Molecular epidemiology of human cancer risk: Gene-environment interactions and p53 mutation spectrum in human lung cancer

Journal of Pathology

Volumn 187, Issue 1, 1999, Pages 8-18

  Bennett, William P ^a   Hussain, S Perwez ^b   Vahakangas, Kirsi H ^c   Khan, Mohammed A ^b   Shields, Peter G ^b   Harris, Curtis C ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF OULU   (Finland)

Author keywords

Environment; Epidemiology; Lung cancer; Molecular biology; Neoplasia; p53

Indexed keywords

GENE PRODUCT; PROTEIN P53;

APOPTOSIS; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHROMOSOME SEGREGATION; DNA DAMAGE; DNA REPAIR; ENVIRONMENTAL FACTOR; GENE MUTATION; HEREDITY; HYPOXIA; LUNG CANCER; MOLECULAR BIOLOGY; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

COCARCINOGENESIS; ENVIRONMENT; GENES, P53; HUMANS; LUNG NEOPLASMS; MUTATION; SMOKING;

EID: 0032907527     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199901)187:1<8::AID-PATH232>3.0.CO;2-Y     Document Type: Review

References (126)

1. International Agency on the Research of Cancer. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans: Tobacco Smoking. Vol. 38. Lyon: IARC, 1986.
2. Harris CC. Chemical and physical carcinogenesis: advances and perspectives. Cancer Res 1991; 51: 5023s-5044s.
3. Perera FP. Molecular epidemiology: insights into cancer susceptibility, risk assessment, and prevention. J Natl Cancer Inst 1996; 88: 496-509.
4. Perera FP. Environment and cancer: who are susceptible? Science 1997; 278: 1068-1073.
5. Ponder B Genetic testing for cancer risk. Science 1997; 278: 1050-1054.
6. Cuzick J, Routledge MN, Jenkins D, Garner RC. DNA adducts in different tissues of smokers and non-smokers. Int J Cancer 1990; 45: 673-678.
7. Phillips DH, Hewer A, Martin CN, Garner RC, King MM. Correlation of DNA adduct levels in human lung with cigarette smoking. Nature 1988; 336: 790-792.
8. Kato S, Bowman ED, Harrington AM, Blomeke B, Shields PG. Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo. J Natl Cancer Inst 1995; 87: 902-907.
9. Ryberg D, Hewer A, Phillips DH, Haugen A. Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients. Cancer Res 1994; 54: 5801-5803.
10. Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Watanabe J. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS 1990; 263: 131-133.
11. Nakachi K, Imai K, Hayashi S, Watanabe J, Kawajiri K. Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res 1991; 51: 5177-5180.
12. Okada T, Kawashima K, Fukushi S, Minakuchi T, Nishimura S. Association between a cytochrome P450 CYP1A1 genotype and incidence of lung cancer. Pharmacogen 1995; 4: 333-340.
13. Hayashi S, Watanabe J, Nakachi K, Kawajiri K. Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J Biochem (Tokyo) 1991; 110: 407-411.
14. Nakachi K, Hayashi S, Kawajiri K, Imai K. Association of cigarette smoking and CYP1A1 polymorphisms with adenocarcinoma of the lung by grades of differentiation. Carcinogenesis 1995; 16: 2209-2213.
15. Goto I, Yoneda S, Yamamoto M, Kawajiri K. Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer. Cancer Res 1996; 56: 3725-3730.
16. Kawajiri K, Eguchi H, Nakachi K, Sekiya T, Yamamoto M. Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res 1996; 56: 72-76.
17. Warren AJ, Shields PG. Molecular epidemiology: carcinogen-DNA adducts and genetic susceptibility. Proc Soc Exp Biol Med 1997; 216: 172-180.
18. Ishibe N, Wiencke JK, Zuo ZF, McMillan A, Spitz M, Kelsey KT. Susceptibility to lung cancer in light smokers associated with CYP1A1 polymorphisms in Mexican-and African-Americans. Cancer Epidemiol Biomarkers Prev 1997; 6: 1075-1080.
19. Seidegard J, Vorachek WR, Pero RW, Pearson WR. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci USA 1988; 85: 7293-7297.
20. Mannervik B, Awasthi YC, Board PG, et al. Nomenclature for human glutathione transferases. Biochem J 1992; 282: 305-306.
21. Wiencke JK, Kelsey KT, Lamela RA, Toscano WA Jr. Human glutathione S-transferase deficiency as a marker of susceptibility to epoxide-induced cytogenetic damage. Cancer Res 1990; 50: 1585-1590.
22. van Poppel G, de Vogel N, van Balderen PJ, Kok FJ. Increased cytogenetic damage in smokers deficient in glutathione S-transferase isozyme mu. Carcinogenesis 1992; 13: 303-305.
23. Norppa H, Hirvonen A, Jarventaus H, et al. Role of GSTT1 and GSTM1 genotypes in determining individual sensitivity to sister chromatid exchange induction by diepoxybutane in cultured human lymphocytes. Carcinogenesis 1995; 16: 1261-1264.
24. Bartsch H, Petruzzelli S, De Flora S. et al. Carcinogen metabolism and DNA adducts in human lung tissues as affected by tobacco smoking or metabolic phenotype: a case-control study on lung cancer patients. Mutat Res 1991: 250; 103-114.
25. Nazar-Stewart V, Motulsky AG, Eaton DL, et al. The glutathione S-transferase mu polymorphism as a marker for susceptibility to lung carcinoma. Cancer Res 1993; 53: 2313-2318.
26. Zhong S, Howie AF, Ketterer B, et al. Glutathione S-transferase mu locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. Carcinogenesis 1991; 12: 1533-1537.
27. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Vainio H. The GSTM1 null genotype as a potential risk modifier for squamous cell carcinoma of the lung. Carcinogenesis 1993; 13: 1479-1481.
28. London SJ, Daly AK, Cooper J, Navidi WC, Carpenter CL, Idle JR. Polymorphism of glutathione S-transferase M1 and lung cancer risk among African-Americans and Caucasians in Los Angeles County. California. J Natl Cancer Inst 1995; 87: 1246-1252.
29. Kihara M, Noda K. Lung cancer risk of GSTM1 null genotype is dependent on the extent of tobacco smoke exposure. Carcinogenesis 1994; 15: 415-418.
30. Brockmöller J, Kerb R, Drakoulis N, Nitz M, Roots I. Genotype and phenotype of glutathione S-transferase class mu isoenzymes mu and psi in lung cancer patients and controls. Cancer Res 1993; 53: 1004-1011.
31. Alexandrie A-K, Sundberg MI, Seidegard J, Tornling G, Rannug A. Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and histological cancer types. Carcinogenesis 1994; 15: 1785-1790.
32. Anttila S, Luostarinen L, Hirvonen A. et al. Pulmonary expression of glutathione S-transferase M3 in lung cancer patients: association with GSTM1 polymorphism, smoking, and asbestos exposure. Cancer Res 1995; 55: 3305-3309.
33. Nakajima T, Elovaara E, Anttila S, et al. Expression and polymorphism of glutathione S-transferase in human lungs: risk factors in smoking-related lung cancer. Carcinogenesis 1995; 16: 707-711.
34. Vaury C, Laine R, Noguiez P, et al. Human glutathione S-transferase M1 null genotype is associated with a high inducibility of cytochrome P450 1A1 gene transcription. Cancer Res 1995; 55: 5520-5523.
35. Nakachi K, Imai K, Hayashi S, Kawajiri K. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res 1993; 53: 2994-2999.
36. Maltzman W, Czyzyk L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 1984; 4: 1689-1694.
37. Kastan MB, Radin AI, Kuerbitz SJ, et al. Levels of p53 protein increase with maturation in human hematopoietic cells. Cancer Res 1991; 51: 4279-4286.
38. Kastan MB, Zhan Q, El-Deiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992; 71: 587-597.
39. Guillouf C, Rosselli F, Krishnaraju K, Moustacchi E, Hoffman B, Liebermann DA. p53 involvement in control of G2 exit of the cell cycle: role in DNA damage-induced apoptosis. Oncogene 1995; 10: 2263-2270.
40. Powell SN, DeFrank JS, Connell P, et al. Differential sensitivity of p53( - ) and p53(+) cells to caffeine-induced radiosensitization of override of G2 delay. Cancer Res 1995; 55: 1643-1648.
41. Nelson WG, Kastan MB. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 1994; 14: 1815-1823.
42. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev 1996; 10: 1054-1072.
43. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.
44. Lane DP, Benchimol S. p53: oncogene or anti-oncogene? Genes Dev 1990; 4: 1-8.
45. Dittmer D, Pati S, Zambetti G, et al. Gain of function mutations in p53. Nature Genet 1993; 4: 42-46.
46. Hsiao M, Low J, Dorn E, et al. Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am J Pathol 1994; 145: 702-714.
47. Hainaut P, Soussi T, Shomer B, et al. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res 1997; 25: 151-157.
48. Soussi T, Caron de Fromentel C, May P. Structural aspects of the p53 protein in relation to gene evolution. Oncogene 1990; 5: 945-952.
49. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
50. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351: 453-456.
51. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-4878.
52. Park M, Vande Woude GF. Principles of molecular cell biology of cancer: oncogenes In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer. Principles & Practice of Oncology. 3rd edn. New York: J. B. Lippincott, 1989, 45-66.
53. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991; 350: 427-428.
54. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350: 429-431.
55. Harris CC. The 1995 Walter Hubert Lecture - Molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumor suppressor gene. Br J Cancer 1996; 73: 261-269.
56. Aguilar F, Harris CC, Sun T, Hollstein M, Cerutti P. Geographic variation of p53 mutational profile in nonmalignant human liver. Science 1994; 264: 1317-1319.
57. Aguilar F, Hussain SP, Cerulti P, Aflatoxin B1 induces the transversion of G→T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci USA 1993; 90: 8586-8590.
58. Mace K, Aguilar F, Wang JS, et al. Aflatoxin B1 induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines Carcinogenesis 1997; 18: 1291-1297.
59. Brash DE, Rudolph JA, Simon JA, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 1991; 88: 10 124-10 128.
60. Brash DE. UV mutagenic photoproducts in Escherichia coli and human cells: a molecular genetics perspective on human skin cancer. Photochem Phatobiol 1988; 48: 59-66.
61. Nakazawa H, English D, Randell PL, et al. UV and skin cancer: specific p53 gene mutation in normal skin as a biologically relevant exposure measurement. Proc Natl Acad Sci USA 1994; 91: 360-364.
62. Ziegler A, Jonason AS, Leffell DJ, et al. Sunburn and p53 in the onset of skin cancer. Nature 1994; 372: 773-776.
63. Takeshima Y, Seyama T, Bennett WP, et al. p53 mutations in lung cancers from non-smoking atomic-bomb survivors. Lancet 1993; 342: 1520-1521.
64. Denissenko MF, Pao A, Tang M, Pfeifer GP. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science 1996; 274: 430-432.
65. Klein-Szanto AJ, lizasa T, Momiki S. et al. A tobacco-specific N-nitrosamine or cigarette smoke condensate causes neoplastic transformation of xenotransplanted human bronchial epithelial cells. Proc Natl Acad Sci USA 1992; 89: 6693-6697.
66. Hill AB. The environment and disease: association or causation. Proc R Soc Med 1965; 58: 295-300.
67. Hussain SP, Harris CC. Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res 1998; 58: 000.
68. Mumford JL, He XZ, Chapman RS, et al. Lung cancer and indoor air pollution in Xuan Wei, China. Science 1987; 235: 217-220.
69. Mumford JL, Helmes CT, Lee XM, Seidenberg J, Nesnow S. Mouse skin tumorigenicity studies of indoor coal and wood combustion emissions from homes of residents in Xuan Wei. China with high lung cancer mortality. Carcinogenesis 1990; 11: 397-403.
70. Ko YC, Lee CH, Chcn MJ, et al. Risk factors for primary lung cancer among non-smoking women in Taiwan. Int J Epidemiol 1997; 26: 24-31.
71. Evans MK, Taffe BG, Harris CC, Bohr VA. DNA strand bias in the repair of the p53 gene in normal human and xeroderma pigmentosum group C fibroblasts. Cancer Res 1993; 53: 5377-5381.
72. Hernandez TM, Hainaut P. A specific spectrum of p53 mutations in lung cancer from smokers: review of mutations compiled in the IARC p53 database. Environ Health Perspect 1998; 106: 385-391.
73. Harris CC. Cause and prevention of lung cancer. Semin Oncol 1974; 1: 163-166.
74. Denissenko MF, Chen JX, Tang MS, Pfeifer GP. Cytosine methylation determines hot spots of DNA damage in the human p53 gene. Proc Natl Acad Sci USA 1997; 94: 3893-3898.
75. Denissenko MF, Pao A, Pfeifer GP, Tang M. Slow repair of bulky DNA adducts along the nontranscribed strand of the human p53 gene may explain the strand bias of transversion mutations in cancers. Oncogene 1998; 16: 1241-1247.
76. Vahakangas KH, Samet JM, Metcalf RA, et al. Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet 1992; 339: 576-580.
77. Bennett WP, Colby TV, Vahakangas KH, et al. p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res 1993; 53: 4817-4822.
78. Sozzi G, Miozzo M, Donghi R, et al. Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res 1992; 52: 6079-6082.
79. Sundaresan V, Ganly P, Hasleton P. et al. p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus. Oncogene 1992; 7: 1989-1997.
80. Wistuba II, Lam S, Behrens C. et al. Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst 1997; 89: 1366-1373.
81. Mao L, Lee JS, Kurie JM, et al. Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 1997; 89: 857-862.
82. Alavanja MC, Brownson RC, Benichou J, Swanson C, Boice JD Jr. Attributable risk of lung cancer in lifetime nonsmokers and long-term ex-smokers (Missouri, United States). Cancer Causes Control 1995; 6: 209-216.
83. Wang TJ, Zhou BS. Meta-analysis of the potential relationship between exposure to environmental tobacco smoke and lung cancer in nonsmoking Chinese women. Lung Cancer 1997; 16: 145-150.
84. Zang EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst 1996; 88: 183-192.
85. Wynder EL, Hoffmann D. Smoking and lung cancer: scientific challenges and opportunities. Cancer Res 1994; 54: 5284-5295.
86. Taioli E, Wynder EL. Re: Endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst 1994; 86: 869-870.
87. Harris RE, Zang EA, Anderson JI, Wynder EL. Race and sex differences in lung cancer risk associated with cigarette smoking. Int J Epidemiol 1993; 22: 592-599.
88. Risch HA, Howe GR, Jain M, Burch JD, Holowaty EJ, Miller AB. Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type. Am J Epidemiol 1993; 138: 281-293.
89. Gao YT, Blot WJ, Zheng W, et al. Lung cancer among Chinese women. Int J Cancer 1987; 40: 604-609.
90. Sellers TA, Potter JD, Folsom AR. Association of incident lung cancer with family history of female reproductive cancers: the Iowa Women's Health Study. Genet Epidemiol 1991; 8: 199-208.
91. Adami HO, Persson I, Hoover R, Schairer C, Bergkvist L. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer 1989; 44: 833-839.
92. Kure EH, Ryberg D, Hewer A. et al. p53 mutations in lung tumours: relationship to gender and lung DNA adduct levels. Carcinogenesis 1996; 17: 2201-2205.
93. Guinee DG, Travis WD, Trivers GE, et al. Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression. Carcinogenesis 1995; 16: 993-1002.
94. Weinberg RA. Tumor suppressor genes. Science 1991; 254: 1138-1146.
95. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260: 1317-1320.
96. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993; 72: 791-800.
97. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993; 363: 515-521.
98. Schimke RN. Genetics and Cancer in Man. New York: Churchill Livingstone, 1978: 18, 26.
99. Soini Y, Chia SC, Bennett WP, et al. An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Carcinogencsis 1996; 17: 1007-1012.
100. Wogan GN. Aflatoxins as risk factors for hepatocellular carcinoma in humans. Cancer Res 1992; 52: 2114s-2118s.
101. Ross RK, Yuan JM, Yu MC, et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992; 339: 943-946.
102. I.A.R.C. Mycotoxins: Aflatoxins: Studies of Cancer in Experimental Animals. In: Anonymous. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Lyon: International Agency for Research on Cancer. 1993; 263-395.
103. Autrup H, Harris CC, Wu SM, et al. Activation of chemical carcinogens by cultured human fetal liver, esophagus and stomach. Chem Biol Interact 1984; 50: 15-25.
104. Pfeifer AMA, Cole KE, Smoot DT, et al. SV40 T-antigen immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens. Proc Natl Acad Sci USA 1993; 90: 5123-5127.
105. Puisieux A, Lim S, Groopman J, Ozturk M. Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. Cancer Res 1991; 51: 6185-6189.
106. Wang XW, Gibson MK, Vermeulen W, et al. Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res 1995; 55: 6012-6016.
107. Forrester K, Lupold SE, Ott VL, et al. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene 1995; 10: 2103-2111.
108. Ponchel F, Puisieux A, Tabone E, et al. Hepatocarcinoma-specific mutant p53-249ser induces mitotic activity but has no effect on transforming growth factor beta 1-mediated apoptosis. Cancer Res 1994; 54: 2064-2068.
109. Chung GT, Sundaresan V, Hasleton P, Rudd R, Taylor R, Rabbitts PH. Sequential molecular genetic changes in lung cancer development. Oncogene 1995; 11: 2591-2598.
110. Chung GT, Sundaresan V, Hasleton P, Rudd R, Taylor R, Rabbitts PH. Clonal evolution of lung tumors. Cancer Res 1996; 56: 1609-1614.
111. Awaya Y, Hiyama K, Yamakido M. [Analysis of oncogenes and suppressor genes in lung cancer and bronchial lesions from high risk group]. Nippon Kyobu Shikkan Gakkai Zasshi 1992; 30 (Suppl.): 39-41 (in Japanese).
112. I.A.R.C. Benzo[a]pyrene. In: Anonymous. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Lyon: International Agency for Research on Cancer, 1983; 211-224.
113. Dipple A. Polynuclear aromatic carcinogens. In: Searle CE, ed. Chemical Carcinogens. ACS Monograph edition. Washington, DC: American Chemical Society, 1976; 245-314.
114. I.A.R.C. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Lyon: IARC, 1986: 7.
115. Harris CC, Genta VM, Frank AL, et al. Carcinogenic polynuclear hydrocarbons bind to macromolecules in cultured human bronchi. Nature 1974; 252: 68-69.
116. Jeffrey AM, Weinstein IB, Jennette KW, et al. Structures of benzo[a]pyrene-nucleic acid adducts formed in human and bovine bronchial expiants. Nature 1977; 269: 348-350.
117. Cherpillod P, Amstad PA Benzo[a]pyrene-induced mutagenesis of p53 hot-spot codons 248 and 249 in human hepatocytes. Mol Carcinog 1995; 13: 15-20.
118. Iizasa T, Momiki S, Bauer B, et al. Invasive tumors derived from xenotransplanted, immortalized human cells after in vivo exposure to chemical carcinogens. Carcinogenesis 1993; 14: 1789-1794.
119. Daya-Grosjean L, Dumaz N, Sarasin A. The specificity of p53 mutation spectra in sunlight induced human cancers. J Photochem Photobiol B 1995; 28: 115-124.
120. I.A.R.C. Studies of cancer in animals. In: Anonymous. IARC Monographs on the Evaluation of Carcinogenic Risk to Humans. Lyon: International Agency for Research on Cancer, 1992; 139-162
121. Tornaletti S, Rozek D, Pfeifer GP. The distribution of UV photoproducts along the human p53 gene and its relation to mutations in skin cancer. Oncogene 1993; 8: 2051-2057.
122. Dumaz N, Drougard C, Sarasin A, Daya-Grosjean L. Specific UV-induced mutation spectrum in the p53 gene of skin tumors from DNA-repair-deficient xerodrma pigmentosum patients. Proc Natl Acad Sci USA 1993; 90: 10 529-10 533.
123. Hsia HC, Lebkowski JS, Leong PM, Calos MP, Miller JH. Comparison of ultraviolet irradiation-induced mutagenesis of the lac1 gene in Excherichia coli and in human 293 cells. J Mol Biol 1989; 205: 103-113.
124. Bredberg A, Kraemer KH, Seidman MM. Restricted ultraviolet mutational spectrum in a shuttle vector propagated in xeroderma pigmentosum cells. Proc Natl Acad Sci USA 1986; 83: 8273-8277.
125. Kress S, Sutter C, Strickland PT, Mukhtar H, Schweizer J, Schwarz M. Carcinogen-specific mutational pattern in the p53 gene in ultraviolet B radiation-induced squamous cell carcinomas of mouse skin. Cancer Res 1992; 52: 6400-6403.
126. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996; 88: 1442-1455